Skip to content

Clinical trials

Phase 2 Stomach Neoplasms trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Stomach Neoplasms Phase: Phase 2 Clear all

774 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
200013
200111
200210
200315
200422
200512
200621
200730
200821
200925
201019
201132
201233
201325
201414
201528
201617
201737
201830
201935
202037
202151
202236
202339
202459
202538
202638

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed287
Unknown status222
Recruiting91
Terminated62
Not yet recruiting54
Active, not recruiting37
Withdrawn15
Suspended5
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Fudan University28
National Cancer Institute (NCI)22
Memorial Sloan Kettering Cancer Center18
The First Affiliated Hospital with Nanjing Medical University14
Peking University13
Tianjin Medical University Cancer Institute and Hospital13
National Cancer Center, Korea12
Chinese Academy of Medical Sciences11
Sun Yat-sen University11
Hoffmann-La Roche10

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Stomach Neoplasms774
Esophageal Neoplasms127
Neoplasm Metastasis38
Colorectal Neoplasms34
Pancreatic Neoplasms33
Adenocarcinoma29
Breast Neoplasms26
Neoplasms26
Ovarian Neoplasms23
Lung Neoplasms20

Trials

Showing 1 to 25 of 774. Each trial links to its page on Pharma Observatory.

674 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.